Evidence map›Paper›PMID 32071925›Full record

ArticleMolecular therapy. Methods & clinical development2020

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.

Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A Konkle, Carol Miao, LinShu Liu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jenni FirrmanDepartment of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA.
Qizhao WangSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Wenman WuSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Biao DongSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Wenjing CaoSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Andrea Rossi MooreSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Sean RobertsSol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA.
Barbara A KonkleBloodworks Northwest, Seattle, WA, USA.
Carol MiaoDepartment of Medicine, University of Washington, Seattle, WA, USA.
LinShu LiuDairy and Functional Foods Research Unit, Agricultural Research Service, Eastern Regional Research Center, Wyndmoor, PA, USA.
Dong LiShanghai Tongji Hospital, Tongji University, Shanghai, P.R. China.
Weidong XiaoDepartment of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA.
Temple University · USUniversity of Washington · USEastern Regional Research Center · USTongji University · CN

Funding

Temple Project 1: Genetic characterization of factor VIII Inhibitors and glydosylation patternsU54HL142019 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI LI, LEI, MIAO, CAROL H · 2018 to 2022
$6.9M
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapyR01HL134321 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2016 to 2026
$6.2M
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia AR01HL151077 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2020 to 2023
$3.2M
Molecular Biology of Recombinant AAV GenomesR01HL080789 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2006 to 2014
$3.1M
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia AR01HL123326 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2016 to 2019
$1.9M
Molecular engineering of factor VIII gene for rAAV deliveryR01HL084381 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2008 to 2012
$1.9M
NHLBI NIH HHS R01 HL080789NHLBI NIH HHS R01 HL084381NHLBI NIH HHS R01 HL123326NHLBI NIH HHS R01 HL134321NHLBI NIH HHS R01 HL151077NHLBI NIH HHS U54 HL142019
6 · The paper itself

Abstract

It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity. The goal of this study was to first determine which amino acids in cFVIII light chain were responsible for enhancing hFVIII activity, and second to use these amino acids to develop a hFVIII variant with enhanced functional activity. We systemically screened segments of cFVIII light chain by testing an array of human-canine light chain hybrids and found that canine amino acids 1857-2147 were key to this enhancement. Each canine amino acid within this span was screened individually using a negative selection method, which led to the identification of 12 aa (JF12) in the FVIII light chain that could enhance activity. Substitution of the corresponding 12 aa into hFVIII (hFVIIIJF12BDD) elevated the specific activity profile

Indexed as

coagulation factor VIIIfactor VIIIFVIII proteingenetic engineeringhemophilia A

Identifiers

PMID32071925
PMCPMC7013134
OpenAlexW2999958198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.